iBio Announces MUC16 as its Latest Immune-Oncology Target Program

Stock Information for iBio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About iBio Inc.

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
iBio Announces $15.0 Million Private Placement
iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
iBio Announces Participation in 23rd Annual PepTalk Conference
iBio Amends and Extends Maturity of Credit Agreement
iBio, Inc. Announces Pricing of $4.5 Million Public Offering
iBio Announces Reverse Stock Split
iBio Further Expands Tech Stack with ShieldTx(TM); Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.